NovoBind Livestock Therapeutics Inc. is a biotechnology company focused on developing nanobody-based biologics aimed at improving animal health and food security. Operating in the animal health market, NovoBind serves livestock producers and the broader agricultural sector by providing advanced solutions to combat diseases such as Salmonella. The company employs a business model that involves research and development, followed by commercialization through strategic partnerships and collaborations. Revenue is generated through the sale of its biologic products and licensing agreements. NovoBind's commitment to sustainability and innovation positions it as a key player in the global effort to enhance food security and promote healthier livestock.

Keywords: nanobody, biologics, animal health, food security, livestock, biotechnology, Salmonella, sustainable practices, innovation, commercialization.